Date			2. Transac Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		Table I - Nor	n-Deriva	tive S	ecurities Acqu	uired,	Disp	osed of, o	or Ben	eficially	Owned			
(City)	(State)	(Zip)	(Zip)								Form filed by M Person	ore than One Rep	porting	
(Street) DEERPARK IL 60010-7208											 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting 			
	ARMACEUTI D PARKWAY,	1				<u></u>								
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 01/03/2025							Officer (give title below) Chief Bu	ve title Other (specify below)		
1. Name and Address of Reporting Person [*] <u>Krempa David</u>				2. Issuer Name and Ticker or Trading Symbol <u>Eton Pharmaceuticals, Inc.</u> [ETON]							k all applicable) Director	10% Ov		
transaction was contract, instru the purchase o securities of the to satisfy the at	to indicate that a s made pursuant to a ction or written plan f r sale of equity a issuer that is inteno firmative defense ule 10b5-1(c). See	for												
Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				pursuar	F CHANGES	Esti		3235-0287 den 0.5						
					wasning	ton, D.C	. 2054	19			OMB APPROVAL			
Section 16. Form 4 or Form 5					Washing	ton, D.C	. 2054	19		HIP OMI Esti	OMB Number: 3235-028 Estimated average burden			

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable = Expiration Date (Month/Day/Year) 6. Date Exercisable = (Month/Day/Year)		ate	e and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$13	01/03/2025		Α		38,621		(1)	01/02/2035	Common Stock	38,621	\$0	38,621	D	
Restricted Stock Units	(2)	01/03/2025		Α		25,876		(3)	(3)	Common Stock	25,876	\$0	25,876	D	

Explanation of Responses:

1. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029.

2. Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.

3. The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

/s/ James R. Gruber	01/06/2025
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.